The above analytical results indicate that the increased expression of STARD4 is highly related to the malignant progression of HCC, which suggests that STARD4 could serve as a biomarker for predicting outcomes in HCC patients. This evidence concerns the gene STARD4 and hepatocellular carcinoma.